{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:40:28Z","timestamp":1789206028436,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001425"],"award-info":[{"award-number":["UL1 TR001425"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.052","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T07:55:52Z","timestamp":1569830152000},"page":"6832-6841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction"],"prefix":"10.1016","volume":"37","author":[{"given":"Lea E.","family":"Widdice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darron R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Ermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-4976","authenticated-orcid":false,"given":"Jessica A.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.052_b0005","unstructured":"Food and Drug Administration. Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18]). Silver Spring, MD: Food and Drug Administration; 2011."},{"key":"10.1016\/j.vaccine.2019.08.052_b0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/infdis\/jix057","article-title":"Prevalence of genital human papillomavirus in males, United States, 2013\u20132014","volume":"215","author":"Gargano","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","article-title":"Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013","volume":"22","author":"Cameron","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0020","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0025","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.08.052_b0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/AOG.0000000000002193","article-title":"Change in human papillomavirus prevalence among U.S. women aged 18\u201359 years, 2009\u20132014","volume":"130","author":"Berenson","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2019.08.052_b0035","first-page":"202","article-title":"Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program","volume":"215","author":"Machalek","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(16)30116-5","article-title":"Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study","volume":"17","author":"Chow","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination \u2013 updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.08.052_b0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/AOG.0b013e31817051fa","article-title":"Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women","volume":"111","author":"Kahn","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2019.08.052_b0055","article-title":"Factors associated with HPV vaccine initiation, vaccine completion, and accuracy of self-reported vaccination status among 13- to 26-year-old men","author":"Thomas","year":"2016","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.vaccine.2019.08.052_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jadohealth.2018.01.005","article-title":"Epidemiology of any and vaccine-type anogenital human papillomavirus among 13\u201326-year-old young men after HPV vaccine introduction","volume":"63","author":"Chandler","year":"2018","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2019.08.052_b0065","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1086\/521629","article-title":"The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study","volume":"196","author":"Giuliano","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.vaccine.2019.08.052_b0075","first-page":"1","article-title":"Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction","author":"Covert","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.08.052_b0080","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1016\/j.vaccine.2017.11.005","article-title":"Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction","volume":"35","author":"Ding","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.052_b0085","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1902","article-title":"Human papillomavirus vaccine effectiveness and herd protection in young women","author":"Spinner","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.08.052_b0090","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2019.08.052_b0095","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","article-title":"The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.052_b0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes","volume":"22","author":"Mesher","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0115","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/ijc.31281","article-title":"Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)","volume":"142","author":"Gray","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.08.052_b0120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.25675","article-title":"Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33","volume":"128","author":"Merikukka","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.08.052_b0125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/aje\/kwu267","article-title":"Concurrence of multiple human papillomavirus infections in a large US population-based cohort","volume":"180","author":"Yang","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.08.052_b0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12879-018-2945-8","article-title":"Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy","volume":"18","author":"Carozzi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw300","article-title":"Evaluation of type replacement following HPV16\/18 vaccination: pooled analysis of two randomized trials","volume":"109","author":"Tota","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2019.08.052_b0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archpediatrics.2012.586","article-title":"Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose","volume":"166","author":"Widdice","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2019.08.052_b0145","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/421279","article-title":"Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea","volume":"190","author":"Shin","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.052_b0150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/aje\/kwf180","article-title":"Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students","volume":"157","author":"Winer","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.08.052_b0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/infdis\/jix588","article-title":"Acquisition, persistence, and clearance of human papillomavirus infection among male virgins residing in Brazil, Mexico, and the United States","volume":"217","author":"Liu","year":"2018","journal-title":"J Infect Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:32Z","timestamp":1759401332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19311260"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}